Mike Romanos Appointed as CEO of Crescendo Biologics

10-Jan-2011 - United Kingdom

Crescendo Biologics Limited announces the appointment of Mike Romanos as Chief Executive Officer. Dr Romanos has been Chief Scientific Officer of the company since May 2009 and has led the formation of the company and the development of its proprietary antibody fragment technologies.

During this time, the company has made significant progress in the establishment of its team and its technology platforms. This has included the establishment of a colony of engineered mice completely devoid of endogenous antibody polypeptides, announced in September. The proprietary ‘triple knockout’ mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion.

Dr Romanos has more than 23 years’ biotech and pharma industry experience and within the last 10 years has held senior global positions leading major parts of GlaxoSmithKline Discovery.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances